THE HUMIRA IN OCULAR INFLAMMATIONS TAPER (HOT) STUDY.

Pichi, Francesco; Smith, Scott D; Goldstein, Debra A; Baddar, Dina; Gerges, Terese K A; Janetos, Timothy M; Ruiz-Cruz, Matilde; Concha-Del-Río, Luz Elena; Maruyama, Kazuichi; Carina Ten Berge, Josianne; Rombach, Saskia M; Cimino, Luca; Bolletta, Elena; Miserocchi, Elisabetta; Scandale, Pierluigi; Serafino, Massimiliano; Camicione, Paola; Androudi, Sofia; Gonzalez-Lopez, Julio J; Lim, Lyndell L; ... (2024). THE HUMIRA IN OCULAR INFLAMMATIONS TAPER (HOT) STUDY. American journal of ophthalmology, 258, pp. 87-98. Elsevier Science 10.1016/j.ajo.2023.09.012

Text 1-s2.0-S000293942300377X-main.pdf - Accepted Version Restricted to registered users only until 19 September 2024. Available under License Publisher holds Copyright. Download (737kB) | Request a copy

PURPOSE

To assess factors that impact the risk of relapse in patients with non-infectious uveitis (NIU) who undergo adalimumab tapering after achieving remission.

DESIGN

Retrospective study.

METHODS

- Setting: Multicenter study. - Study Population: Patients with NIU treated with adalimumab and subsequently tapered. - Observation Procedure: Patient demographics, type of NIU, onset and duration of disease, period of inactivity before tapering adalimumab and tapering schedule were collected. - Main Outcome Measures: Independent predictors of the rate of uveitis recurrence after adalimumab tapering.

RESULTS

328 patients were included (54.6% female) with a mean age of 34.3 years. The mean time between disease onset and initiation of adalimumab therapy was 35.2±70.1 weeks. Adalimumab tapering was commenced after a mean of 100.8±69.7 weeks of inactivity. Recurrence was observed in 39.6% of patients at a mean of 44.7±61.7 weeks. Patients who experienced recurrence were significantly younger than those without recurrence (mean 29.4 years vs. 37.5 years, p=0.0005) and the rate of recurrence was significantly higher in younger subjects (HR=0.88 per decade of increasing age, p=0.01). The lowest rate of recurrence was among Asian subjects. A faster adalimumab taper was associated with an increased recurrence rate (HR=1.23 per unit increase in speed, p<0.0005). Conversely, a more extended period of remission prior to tapering was associated with a lower rate of recurrence (HR=0.97 per 10-weeks longer period of inactivity, p=0.04).

CONCLUSIONS

When tapering adalimumab, factors that should be considered include patient's age, race, and duration of disease remission on adalimumab. A slow tapering schedule is advisable.

Interest & Impact

Downloads

0 since deposited on 26 Sep 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item